Cerus Corporation has reported its financial results for the second quarter of 2025. The company's total revenue for this period was highlighted by record product sales, prompting an upward revision in the full-year 2025 product revenue guidance, now projected to be between $194 million and $200 million. This includes expected revenue from IFC products ranging from $12 million to $15 million. For the second quarter of 2025, Cerus recorded a net loss attributable to the corporation of $5.7 million, consistent with a net loss of $5.8 million in the same quarter of the previous year. The net loss for the first half of 2025 was $13.4 million, showing an improvement from a $15.5 million net loss in the first half of 2024. Non-GAAP adjusted EBITDA for the second quarter of 2025 was positive at $0.9 million, slightly up from $0.8 million in the prior year period. For the first half of 2025, non-GAAP adjusted EBITDA was a positive $1.1 million, compared to a negative $1.9 million in the first half of 2024, reflecting a significant turnaround. The company is committed to achieving positive, full-year 2025 non-GAAP adjusted EBITDA. As of June 30, 2025, Cerus held $78 million in cash, cash equivalents, and short-term investments, with a revolving line of credit permitting an additional $15 million subject to asset eligibility. Cash used from operations during the second quarter totaled $2.4 million. These results indicate a continued strong commercial and financial execution, further supported by a recent Department of Defense award for the CRYO-First study.